Alkermes (ALKS) shifts to fully integrated biopharma, leveraging Vibrance-2, Lybalvi growth, and Avadel buy to de-risk ...
Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; ...
These synthetic compounds — known as per- and polyfluoroalkyl substances, or PFAS — could as much as triple the chances ...
PFOAS, or forever chemicals, are everywhere nowadays. Exposure is unavoidable, but teens appear especially vulnerable ...
A new study co-led by the Southern California Superfund Research and Training Program for PFAS Assessment, Remediation and ...
A new study co-led by the Southern California Superfund Research and Training Program for PFAS Assessment, Remediation and ...
Phase 1 results confirm investigational drug-candidate G1090N has a favorable safety and tolerability profile, supporting further clinical ...
The FDA rejected Sanofi's MS drug tolebrutinib, citing liver injury risks, unclear benefits, and trial data that failed to ...
Less than two weeks after rejecting Sanofi’s investigational multiple sclerosis drug, the FDA has publicly shared the ...
Scientists have found that combining silybin with carvedilol works far better against liver fibrosis than either drug alone.
Shares of Altimmune, Inc. (NASDAQ: ALT) are rising Monday after the FDA granted Breakthrough Therapy Designation for Pemvidutide.
Drinking diet soda doesn't cause liver damage but can contribute to fatty liver disease due to artificial sweeteners and other risk factors. Learn more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback